96 results about "Neuromuscular junction" patented technology

The present disclosure relates to neuromuscular stimulation and sensing cuffs. The neuromuscular stimulation cuff has at least two fingers and a plurality of electrodes disposed on each finger. More generally, the neuromuscular stimulation cuff includes an outer, reusable component and an inner, disposable component. One or more electrodes are housed within the reusable component. The neuromuscular stimulation cuff may be produced by providing an insulating substrate layer, forming a conductive circuit on the substrate layer to form a conductive circuit layer, adhering a cover layer onto the conductive circuit layer to form a flexible circuit, and cutting at least one flexible finger from the flexible circuit. The neuromuscular stimulation cuff employs a flexible multi-electrode design which allows for reanimation of complex muscle movements in a patient, including individual finger movement.

A system and a method that promotes the restoration of physical functions of the neuromuscular system by incorporating into one device the treatment modalities of biofeedback based repetitive practice, includes an actuator, a joint position measurement system, a force sensing measurement system, an EMG measurement system, a neuromuscular low-level stimulation system, a controller, and a display device.

A system and a method that promotes the restoration of physical functions of the neuromuscular system by incorporating into one device the treatment modalities of biofeedback based repetitive practice, includes an actuator, a joint position measurement system, a force sensing measurement system, an EMG measurement system, a neuromuscular low-level stimulation system, a controller, and a display device.

A system and method that provide a prophylactic treatment to a person, e.g., a patient, to avoid the occurrence of pulmonary embolisms by the system providing neuromuscular stimulation to a person's lower extremities, e.g., the person's legs, when the system senses that a person has been immobile for an extended period of time. An implantable neuromuscular pacer, such as that described in U.S. Pat. Nos. 5,193,539; 5,193,540; 6,164,284; 6,185,452; 6,208,894; 6,315,721; 6,564,807; and their progeny, may be used to provide to selectively provide such stimulation. Preferably, such a device may be battery powered so that it can operate independent of an external apparatus. In particular, systems and devices of the present invention preferably additionally include an activity monitor, e.g., an accelerometer or the like, that disables or limits stimulation to pronged time periods in which there is limited activity.

Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cleave the synaptosomal proteins, SNAP-25, VAMP, or syntaxin at discrete sites. The present invention relates to the construction, expression, purification, and use of synthetic or recombinant botulinum neutoroxin genes. For example, a synthetic gene for the LC of the botulinum neurotoxin serotype A (BoNT / A) was constructed and overexpressed in Escherichia coli. The gene product was purified from inclusion bodies. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product was stable in solution at 4° C. for at least 6 months. This rBoNT / A LC was proteolytically active, specifically cleaving the Glu-Arg bond in a 17-residue synthetic peptide of SNAP-25, the reported cleavage site of BoNT / A. Its calculated catalytic efficiency kcat / Km was higher than that reported for the native BoNT / A dichain. Treating the rBoNT / A LC with mercuric compounds completely abolished its activity, most probably by modifying the cysteine-164 residue located in the vicinity of the active site. About 70% activity of the LC was restored by adding Zn2+ to a Zn2+-free, apo-LC preparation. The LC was nontoxic to mice and failed to elicit neutralizing epitope(s) when the animals were vaccinated with this protein. In addition, injecting rBoNT / A LC into sea urchin eggs inhibited exocytosis-dependent plasma membrane resealing.

A wearable neuromuscular stimulation and neuroprosthetic system and device for treating spinal cord injury, stroke, and other neurological conditions; and for the management of chronic pain. This invention provides a system for transcutaneous neuromuscular stimulation and typically comprises a wearable item that further includes a flexible, non-conductive material; at least one flexible, generally flat electrode attachable to or embedded within the wearable item; and a programmable electrical stimulation device connectable to the electrode(s). Each electrode typically includes a silver-impregnated or silver-treated material.

The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.